APRESOLINE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jan 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
APRESOLINE (hydralazine) is an oral small-molecule vasodilator approved in 1953 for hypertension management. The exact mechanism and clinical indications are not fully specified in available data, but it represents a legacy antihypertensive therapy from the mid-20th century. It is administered as an oral tablet.
LOE Approaching
As LOE approaches, the brand team is likely consolidating to defensive roles focused on retention and cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
APRESOLINE currently has zero linked open positions, reflecting its mature lifecycle stage and minimal growth trajectory. Careers on this product are typically limited to defensive commercial roles focused on maintaining formulary status, managing pricing pressure, and optimizing existing market penetration rather than growth or innovation-driven opportunities.
Brand Manager (Defensive)
Worked on APRESOLINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.